{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:06Z","timestamp":1794047526867,"version":"4.8.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ondansetron is a selective 5-hydroxytryptamine type 3 serotonin-receptor antagonist with antiemetic properties used inadvertently in the emergency department for controlling nausea. However, ondansetron is linked with a number of adverse effects, including prolongation of the QT interval. Therefore, the purpose of this meta-analysis was to assess the occurrence of QT prolongation in pediatric, adult, and elderly patients receiving oral or intravenously administered ondansetron.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A thorough electronic search was conducted on PubMed (Medline) and Cochrane Library from the databases' inception to August 10, 2022. Only those studies were considered in which ondansetron was administered orally or intravenously to participants for the treatment of nausea and vomiting. The prevalence of QT prolongation in multiple predefined age groups was the outcome variable. Analyses were conducted using Review manager 5.4 (Cochrane collaboration, 2020).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 10 studies involving 687 ondansetron group participants were statistically analyzed. The administration of ondansetron was associated with a statistically significant prevalence of QT prolongation in all age groups. An age-wise subgroup analysis was conducted which revealed that the prevalence of QT prolongation among participants younger than 18\u00a0years was not statistically significant, whereas it was statistically significant among participants aged 18\u201350\u00a0years and among patients older than 50\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present meta-analysis provides further evidence that oral or intravenous administration of Ondansetron may lead to QT prolongation, particularly among patients older than 18\u00a0years of age.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43044-023-00385-y","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T13:03:00Z","timestamp":1688389380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Ondansetron-induced QT prolongation among various age groups: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"75","author":[{"given":"Kamaldeep","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishita","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hritik","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anubhav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakanksha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surabhi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastas","family":"Kostojchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anmol","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishanjit Singh","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loveleen","family":"Bhogal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiny Teja","family":"Kolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal Reddy","family":"Bejugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salil","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-7280","authenticated-orcid":false,"given":"Shobhit","family":"Piplani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"385_CR1","unstructured":"Griddine A, Bush JS (2022) Ondansetron"},{"key":"385_CR2","unstructured":"Ondansetron - Drug Usage Statistics, ClinCalc DrugStats Database. Accessed September 18, 2022. https:\/\/clincalc.com\/DrugStats\/Drugs\/Ondansetron"},{"issue":"5","key":"385_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2020.0050","volume":"81","author":"MS Dulay","year":"2020","unstructured":"Dulay MS, Dulay JS (2020) Antiemetics: types, actions and uses. Br J Hosp Med (Lond) 81(5):1\u20138. https:\/\/doi.org\/10.12968\/hmed.2020.0050","journal-title":"Br J Hosp Med (Lond)"},{"issue":"10","key":"385_CR4","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1136\/gutjnl-2013-305989","volume":"63","author":"K Garsed","year":"2014","unstructured":"Garsed K, Chernova J, Hastings M et al (2014) A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 63(10):1617\u20131625. https:\/\/doi.org\/10.1136\/gutjnl-2013-305989","journal-title":"Gut"},{"issue":"16","key":"385_CR5","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1056\/NEJMoa055119","volume":"354","author":"SB Freedman","year":"2006","unstructured":"Freedman SB, Adler M, Seshadri R, Powell EC (2006) Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med 354(16):1698\u20131705. https:\/\/doi.org\/10.1056\/NEJMoa055119","journal-title":"N Engl J Med"},{"issue":"5","key":"385_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.annemergmed.2009.11.011","volume":"55","author":"JJ Sturm","year":"2010","unstructured":"Sturm JJ, Hirsh DA, Schweickert A, Massey R, Simon HK (2010) Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses? Ann Emerg Med 55(5):415\u2013422. https:\/\/doi.org\/10.1016\/j.annemergmed.2009.11.011","journal-title":"Ann Emerg Med"},{"issue":"Supplement_1","key":"385_CR7","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1093\/pch\/pxab061.082","volume":"26","author":"S Rogers","year":"2021","unstructured":"Rogers S, Freedman S, Klassen T, Burstein B (2021) 101 National trends in emergency department ondansetron use and clinical outcomes among children with acute gastroenteritis. Paediatr Child Health 26(Supplement_1):e72\u2013e73. https:\/\/doi.org\/10.1093\/pch\/pxab061.082","journal-title":"Paediatr Child Health"},{"issue":"3","key":"385_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/PEC.0b013e3182494d87","volume":"28","author":"JJ Sturm","year":"2012","unstructured":"Sturm JJ, Pierzchala A, Simon HK, Hirsh DA (2012) Ondansetron use in the pediatric emergency room for diagnoses other than acute gastroenteritis. Pediatr Emerg Care 28(3):247\u2013250. https:\/\/doi.org\/10.1097\/PEC.0b013e3182494d87","journal-title":"Pediatr Emerg Care"},{"issue":"5","key":"385_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/AOG.0000000000001375","volume":"127","author":"LL Siminerio","year":"2016","unstructured":"Siminerio LL, Bodnar LM, Venkataramanan R, Caritis SN (2016) Ondansetron use in pregnancy. Obstet Gynecol 127(5):873\u2013877. https:\/\/doi.org\/10.1097\/AOG.0000000000001375","journal-title":"Obstet Gynecol"},{"issue":"2","key":"385_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/pds.5143","volume":"30","author":"EA Suarez","year":"2021","unstructured":"Suarez EA, Boggess K, Engel SM, St\u00fcrmer T, Lund JL, Jonsson FM (2021) Ondansetron use in early pregnancy and the risk of miscarriage. Pharmacoepidemiol Drug Saf 30(2):103\u2013113. https:\/\/doi.org\/10.1002\/pds.5143","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"385_CR11","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1177\/08830738020170111706","volume":"17","author":"RB Khan","year":"2002","unstructured":"Khan RB (2002) Migraine-type headaches in children receiving chemotherapy and ondansetron. J Child Neurol 17(11):857\u2013858. https:\/\/doi.org\/10.1177\/08830738020170111706","journal-title":"J Child Neurol"},{"issue":"4","key":"385_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1517\/14656566.9.4.645","volume":"9","author":"EA Jones","year":"2008","unstructured":"Jones EA (2008) Pruritus and fatigue associated with liver disease: is there a role for ondansetron? Expert Opin Pharmacother 9(4):645\u2013651. https:\/\/doi.org\/10.1517\/14656566.9.4.645","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"385_CR13","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1111\/j.1528-1167.2009.02139.x","volume":"50","author":"NN Singh","year":"2009","unstructured":"Singh NN, Rai A, Selhorst JB, Acharya JN (2009) Ondansetron and seizures. Epilepsia 50(12):2663\u20132666. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02139.x","journal-title":"Epilepsia"},{"issue":"10","key":"385_CR14","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1517\/14740338.2014.954546","volume":"13","author":"L Brygger","year":"2014","unstructured":"Brygger L, Herrstedt J, Academy of Geriatric Cancer Research (AgeCare) (2014) 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. Expert Opin Drug Saf 13(10):1407\u20131422. https:\/\/doi.org\/10.1517\/14740338.2014.954546","journal-title":"Expert Opin Drug Saf"},{"key":"385_CR15","unstructured":"FDA Drug Safety Communication: Abnormal heart rhythms may be associated with use of Zofran (ondansetron) | FDA. Accessed September 18, 2022. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-abnormal-heart-rhythms-may-be-associated-use-zofran-ondansetron"},{"key":"385_CR16","unstructured":"FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran) | FDA. Accessed September 18, 2022. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-new-information-regarding-qt-prolongation-ondansetron-zofran"},{"key":"385_CR17","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. https:\/\/doi.org\/10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"385_CR18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"385_CR19","unstructured":"Ottawa Hospital Research Institute. Accessed September 18, 2022. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"2","key":"385_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/ALN.0b013e31817fd8c8","volume":"109","author":"B Charbit","year":"2008","unstructured":"Charbit B, Alvarez JC, Dasque E, Abe E, D\u00e9molis JL, Funck-Brentano C (2008) Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. Anesthesiology 109(2):206\u2013212. https:\/\/doi.org\/10.1097\/ALN.0b013e31817fd8c8","journal-title":"Anesthesiology"},{"issue":"5","key":"385_CR21","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1213\/ane.0b013e31816091f0","volume":"106","author":"L Grecu","year":"2008","unstructured":"Grecu L, Bittner EA, Kher J, Smith SE, Rosow CE (2008) Haloperidol plus ondansetron versus ondansetron alone for prophylaxis of postoperative nausea and vomiting. Anesth Analg 106(5):1410\u20131413. https:\/\/doi.org\/10.1213\/ane.0b013e31816091f0","journal-title":"Anesth Analg"},{"issue":"5","key":"385_CR22","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1213\/ane.0b013e3181609022","volume":"106","author":"CE Rosow","year":"2008","unstructured":"Rosow CE, Haspel KL, Smith SE, Grecu L, Bittner EA (2008) Haloperidol versus ondansetron for prophylaxis of postoperative nausea and vomiting. Anesth Analg 106(5):1407\u20131409. https:\/\/doi.org\/10.1213\/ane.0b013e3181609022","journal-title":"Anesth Analg"},{"issue":"1","key":"385_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/0019-5049.108560","volume":"57","author":"A Ganjare","year":"2013","unstructured":"Ganjare A, Kulkarni AP (2013) Comparative electrocardiographic effects of intravenous ondansetron and granisetron in patients undergoing surgery for carcinoma breast: a prospective single-blind randomised trial. Indian J Anaesth 57(1):41\u201345. https:\/\/doi.org\/10.4103\/0019-5049.108560","journal-title":"Indian J Anaesth"},{"issue":"11","key":"385_CR24","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/jcph.322","volume":"54","author":"P Zuo","year":"2014","unstructured":"Zuo P, Haberer LJ, Fang L, Hunt TL, Ridgway D, Russo MW (2014) Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double-blind, placebo-, and active-controlled thorough QT study. J Clin Pharmacol 54(11):1221\u20131229. https:\/\/doi.org\/10.1002\/jcph.322","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"385_CR25","first-page":"111","volume":"18","author":"A Jamwal","year":"2016","unstructured":"Jamwal A, Jatindera M, Wakhloo R, Kour R (2016) Safety profile of various 5HT3 receptor antagonists used for PONV prophylaxis. JK Sci 18(2):111\u2013115","journal-title":"JK Sci"},{"issue":"5","key":"385_CR26","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ajem.2017.10.004","volume":"36","author":"RJ Hoffman","year":"2018","unstructured":"Hoffman RJ, Alansari K (2018) Effect of intravenous ondansetron on QTc interval in children with gastroenteritis. Am J Emerg Med 36(5):754\u2013757. https:\/\/doi.org\/10.1016\/j.ajem.2017.10.004","journal-title":"Am J Emerg Med"},{"issue":"12","key":"385_CR27","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1080\/15563650.2020.1746330","volume":"58","author":"SL Campleman","year":"2020","unstructured":"Campleman SL, Brent J, Pizon AF et al (2020) Drug-specific risk of severe QT prolongation following acute drug overdose. Clin Toxicol (Phila) 58(12):1326\u20131334. https:\/\/doi.org\/10.1080\/15563650.2020.1746330","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"385_CR28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s12887-021-02937-0","volume":"21","author":"H Yang","year":"2021","unstructured":"Yang H, Jeon W, Ko Y, Jeong S, Lee J (2021) The effect of oral ondansetron on QT interval in children with acute gastroenteritis; a retrospective observational study. BMC Pediatr 21(1):501. https:\/\/doi.org\/10.1186\/s12887-021-02937-0","journal-title":"BMC Pediatr"},{"key":"385_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ajem.2021.06.029","volume":"55","author":"H Sutherland","year":"2022","unstructured":"Sutherland H, Miller M, Tomanec A, Xu KT, Barton T, Richman P (2022) QTc interval changes following low-dose ondansetron administration in the emergency department. Am J Emerg Med 55:201\u2013202. https:\/\/doi.org\/10.1016\/j.ajem.2021.06.029","journal-title":"Am J Emerg Med"},{"issue":"3","key":"385_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2174\/1573403x10666140514103612","volume":"10","author":"PG Postema","year":"2014","unstructured":"Postema PG, Wilde AAM (2014) The measurement of the QT interval. Curr Cardiol Rev 10(3):287\u2013294. https:\/\/doi.org\/10.2174\/1573403x10666140514103612","journal-title":"Curr Cardiol Rev"},{"issue":"3","key":"385_CR31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s11606-019-05477-7","volume":"35","author":"P Indraratna","year":"2020","unstructured":"Indraratna P, Tardo D, Delves M, Szirt R, Ng B (2020) Measurement and management of QT interval prolongation for general physicians. J Gen Intern Med 35(3):865\u2013873. https:\/\/doi.org\/10.1007\/s11606-019-05477-7","journal-title":"J Gen Intern Med"},{"key":"385_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejphar.2016.07.020","volume":"789","author":"MP Van\u2019t Klooster","year":"2016","unstructured":"Van\u2019t Klooster MP, Foadi N, Hage A et al (2016) Local-anesthetic like inhibition of the cardiac sodium channel Nav1.5 \u03b1-subunit by 5-HT3 receptor antagonists. Eur J Pharmacol 789:119\u2013126. https:\/\/doi.org\/10.1016\/j.ejphar.2016.07.020","journal-title":"Eur J Pharmacol"},{"key":"385_CR33","doi-asserted-by":"publisher","first-page":"CD012859","DOI":"10.1002\/14651858.CD012859.pub2","volume":"10","author":"S Weibel","year":"2020","unstructured":"Weibel S, R\u00fccker G, Eberhart LH et al (2020) Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. Cochrane Database Syst Rev 10:CD012859. https:\/\/doi.org\/10.1002\/14651858.CD012859.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"385_CR34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-015-0379-3","volume":"13","author":"AC Tricco","year":"2015","unstructured":"Tricco AC, Soobiah C, Blondal E et al (2015) Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. BMC Med 13:142. https:\/\/doi.org\/10.1186\/s12916-015-0379-3","journal-title":"BMC Med"},{"issue":"1","key":"385_CR35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12916-016-0761-9","volume":"14","author":"AC Tricco","year":"2016","unstructured":"Tricco AC, Blondal E, Veroniki AA et al (2016) Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis. BMC Med 14(1):216. https:\/\/doi.org\/10.1186\/s12916-016-0761-9","journal-title":"BMC Med"},{"issue":"1","key":"385_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/PEC.0000000000000757","volume":"34","author":"SK Krammes","year":"2018","unstructured":"Krammes SK, Jacobs T, Clark JM, Lutes RE (2018) Effect of intravenous ondansetron on the QT interval of patients\u2019 electrocardiograms. Pediatr Emerg Care 34(1):38\u201341. https:\/\/doi.org\/10.1097\/PEC.0000000000000757","journal-title":"Pediatr Emerg Care"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-023-00385-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-023-00385-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-023-00385-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T13:13:46Z","timestamp":1688390026000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-023-00385-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1186\/s43044-023-00385-y","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}